Showing results (11-20 of 79) with videos related to
Sort By:
Pageof 8
Journal of Sports Sciences|April 8, 2025
No ergogenic effect of ischemic preconditioning applied 5 or 30 min before maximal self-paced cycling exerciseAlex Isidori, Liam O'Brien, Ira JacobsBreast (Edinburgh, Scotland)|February 26, 2017
Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilarsChristian Jackisch, Philip Lammers, Ira JacobsMedicine and Science in Sports and Exercise|June 5, 2003
Effects of ephedrine, caffeine, and their combination on muscular enduranceIra Jacobs, Harley Pasternak, Douglas G BellAviation, Space, and Environmental Medicine|June 20, 2006
Physical conditioning to enhance +Gz tolerance: issues and current understandingWilliam A Bateman, Ira Jacobs, Fred BuickCancer Management and Research|May 9, 2017
Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscapeJanakiraman Subramanian, Jamie Cavenagh, Bhardwaj Desai, et al.Biologics : Targets & Therapy|March 4, 2017
Biosimilars and the extrapolation of indications for inflammatory conditionsJohn Rp Tesser, Daniel E Furst, Ira JacobsBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 13, 2017
Biosimilars for the Treatment of Cancer: A Systematic Review of Published EvidenceIra Jacobs, Reginald Ewesuedo, Sadiq Lula, et al.Drugs|March 5, 2017
The Language of Biosimilars: Clarification, Definitions, and Regulatory AspectsPaul Declerck, Romano Danesi, Danielle Petersel, et al.Clinical Breast Cancer|March 12, 2018
The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast CancerKimberly Blackwell, Joseph Gligorov, Ira Jacobs, et al.Pharmaceuticals (Basel, Switzerland)|May 10, 2014
Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician SurveyWilliam H Baer Ii, Archana Maini, Ira JacobsPageof 8